On Tuesday, in the course of current trade, Shares of Clean Diesel Technologies Inc. (NASDAQ:CDTI), surged 24.88%, and is now trading at $2.56.
Clean Diesel Technologies, declared initial vehicle test results for Spinel(TM), its proprietary clean emissions exhaust technology that is predictable to dramatically reduce the cost for auto manufacturers to attain increasingly stringent clean air standards.
Initial vehicle tests were conducted at an independent test facility using the industry standard Federal Test Procedure (FTP) on a model year 2014 Buick Regal 2.0 liter turbo-charged gasoline direct injection (GDI) engine. The data demonstrated that a Spinel underfloor catalyst with 97% less platinum group metal (PGM) achieved emissions control performance equivalent to the OEM catalyst. The Spinel catalyst PGM loading was 2g/ft3 contrast to 59g/ft3 for the OEM catalyst. The Spinel catalyst at 2g/ft3 also offered equivalent performance to the OEM catalyst at 22g/ft3 on a 2014 Toyota Camry with a 2.5 liter naturally-aspirated engine — a PGM savings of 91%. For many passenger cars, these levels of PGM reduction could translate into double-digit dollar cost savings per vehicle, reinforcing Spinel’s strong value proposition for OEMs.
Clean Diesel Technologies, Inc. manufactures and distributes light duty vehicle catalysts and heavy duty diesel emissions control systems and products to automakers, distributors, integrators, and retrofitters in the United States, Canada, Sweden, and the United Kingdom.
During an Afternoon trade, Shares of Halcón Resources Corporation (NYSE:HK), climbed 23.36%, and is now trading at $1.32 as oil prices were higher Tuesday as the dollar weakened and investors felt more confident that the Organization of the Petroleum Exporting Countries would maintain its production aim at its Friday meeting.
Till now, 9,764,651 shares changed hands as compared to its average daily volume of 5,183,740. The company has market capitalization of 772.83M.
Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States.
Finally, HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), jumped nearly 18.21% Tuesday, hitting its highest level.
HTG Molecular Diagnostics, stated financial results for the three months ended March 31, 2015.
Recent Accomplishments & Highlights:
- Accomplished initial public offering, receiving net proceeds of $44.2 million
- Accomplished research agreement with MD Anderson Cancer Center for Targeted Sequencing-based expression panels for lung cancer classification, fusion status and immune profiling
- Collaborated with advisory groups on suggested changes to the Genomic Sequencing Procedure codes which were accepted by the CPT Editorial Panel, and HTG Lung Fusion & Insertion panel received Z-Code from the McKesson Diagnostics Exchange
- Achieved revenue of $1.0 million in the first quarter of 2015, an enhance of 24% over the first quarter of the preceding year
- Launched Oncology Biomarker Panel, the second profiling panel on the HTG EdgeSeq platform.
HTG Molecular Diagnostics, Inc. develops and markets a technology platform that facilitates the routine use of complex molecular profiling. The company’s HTG Edge platform comprises of instrumentation, consumables, and software analytics that are used in sample profiling applications, counting tumor profiling, molecular diagnostic testing, and biomarker development.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
